Our Faculty : Primary Faculty

Emmanuel Thomas M.D., Ph.D., FAASLD

The mission of Dr. Thomas’s program is to develop integrated, multidisciplinary approaches to the study of liver cancer/liver diseases and to bridge clinical medicine and basic science with translation of fundamental knowledge to prevention, diagnosis, and treatment of liver diseases. Dr. Thomas is a Fellow of the American Association for the Study of Liver Diseases (FAASLD). He serves on the National Advisory Board of the American Liver Foundation and he is on the editorial board of Hepatology, Journal of Infectious Diseases and Journal of Translational Medicine. Dr. Thomas currently has over $4million dollars in program support through the National Institutes of Health (NIH) and the Florida Department of Health (FL-DOH).

Since completing a Doris Duke Clinical Fellowship and graduating from the University of Miami Miller School of Medicine in May 2007 simultaneously obtaining both the MD and PhD degrees, Dr. Thomas has made steady progress toward creating and implementing a translational research program focused on preventing liver disease and hepatocellular carcinoma. His program leverages resources and clinical/scientific expertise available through the Miami CTSI, the Schiff Center for Liver Diseases, the Sylvester Comprehensive Cancer Center and the Miami Center for AIDS Research to address the rapid development of liver disease and Hepatocellular Carcinoma which occurs in patients with viral hepatitis. Infection by the Hepatitis B and C viruses and HIV impacts our South Florida community significantly and our efforts will help minimize their detrimental effects in our catchment area.

Having been raised in Miami-Dade county, Dr. Thomas has a strong commitment to improving the health of our local community. Through community screening programs, we are identifying HCV infected individuals and linking them to care so that they can be cured of this deadly virus. In addition, we are also facilitating the ability of uninsured patients to receive these costly medications through patient assistance programs. In addition, we are studying the mechanisms underlying how viral hepatitis (HBV and HCV) cause hepatocellular carcinoma. Lastly, we are developing prediction models to identify patients that are most at risk for developing hepatocellular carcinoma.